At the same time, a decrease in JunB expression was shown in the peripheral blood of patients with chronic myelogenous leukemia [166,167], which indicates the prospects of considering AP-1 as a marker of the progression of malignant neoplasms. This evidence concerns the gene FOS and chronic myelogenous leukemia, BCR-ABL1 positive.